Dr Matteo Fabbri
@drmatteofabbri.bsky.social
Cardiology fellow at Inova. My opinions are my own. He/Him. BLM. Passionate about heart failure and pulmonary hypertension. ❤️
Dr Bilgili showed us the outcomes after OHTx divided by need of ECMO at 72 hours post surgery. ECMO need at 72 hours greatly worsens survival.
April 30, 2025 at 5:58 PM
Dr Bilgili showed us the outcomes after OHTx divided by need of ECMO at 72 hours post surgery. ECMO need at 72 hours greatly worsens survival.
Dr Huang shows pre and post allocation change status change in immunosuppression and outcomes among multi-organ transplant.
Super interesting data. @ishlt.bsky.social #ISHLT2025
Super interesting data. @ishlt.bsky.social #ISHLT2025
April 30, 2025 at 5:49 PM
Dr Huang shows pre and post allocation change status change in immunosuppression and outcomes among multi-organ transplant.
Super interesting data. @ishlt.bsky.social #ISHLT2025
Super interesting data. @ishlt.bsky.social #ISHLT2025
Dr Elbert Heng shows amazing study on survival of patients with ACHD receiving OHTx vs multiorgan transplant alone.
❤️ and 🫁 carry the worse survival so far.
@ishlt.bsky.social #ISHLT2025
❤️ and 🫁 carry the worse survival so far.
@ishlt.bsky.social #ISHLT2025
April 30, 2025 at 5:35 PM
Dr Elbert Heng shows amazing study on survival of patients with ACHD receiving OHTx vs multiorgan transplant alone.
❤️ and 🫁 carry the worse survival so far.
@ishlt.bsky.social #ISHLT2025
❤️ and 🫁 carry the worse survival so far.
@ishlt.bsky.social #ISHLT2025
Dr Paula Ramirez shows us their new predictive models to discriminate if ❤️ and kidney transplant is superior to kidney after ❤️. Beautiful work which can help change clinical practice at #ISHLT2025 @ishlt.bsky.social
April 30, 2025 at 5:22 PM
Dr Paula Ramirez shows us their new predictive models to discriminate if ❤️ and kidney transplant is superior to kidney after ❤️. Beautiful work which can help change clinical practice at #ISHLT2025 @ishlt.bsky.social
Amazing work presented from Dr Topkara who developed a kidney risk score which predicts the risk for AKI/HD after ❤️ transplant! High AUC, higher than eGFR alone!
#ISHLT2025 @ishlt.bsky.social
#ISHLT2025 @ishlt.bsky.social
April 30, 2025 at 5:10 PM
Amazing work presented from Dr Topkara who developed a kidney risk score which predicts the risk for AKI/HD after ❤️ transplant! High AUC, higher than eGFR alone!
#ISHLT2025 @ishlt.bsky.social
#ISHLT2025 @ishlt.bsky.social
Dr Hussain showed us a single center experience of Fontain patients receiving ❤️ transplant. Should they get a liver as well? Seems like all 24 of them had recovery of the liver function after transplant without needing a a new liver.
Great science at #ISHLT2025 @ishlt.bsky.social
Great science at #ISHLT2025 @ishlt.bsky.social
April 30, 2025 at 4:56 PM
Dr Hussain showed us a single center experience of Fontain patients receiving ❤️ transplant. Should they get a liver as well? Seems like all 24 of them had recovery of the liver function after transplant without needing a a new liver.
Great science at #ISHLT2025 @ishlt.bsky.social
Great science at #ISHLT2025 @ishlt.bsky.social
Finally we talk about induction with Dr Barten. To induce or not to induce? This is the dilemma!
And Dr Carboni showed us how AI can be implemented in helping us with HLA matching.
And Dr Carboni showed us how AI can be implemented in helping us with HLA matching.
April 30, 2025 at 4:46 PM
Finally we talk about induction with Dr Barten. To induce or not to induce? This is the dilemma!
And Dr Carboni showed us how AI can be implemented in helping us with HLA matching.
And Dr Carboni showed us how AI can be implemented in helping us with HLA matching.
It’s AB0ut time we talk with Dr Aversa about AB0! Super interesting case of an 0 patient receiving nonA1 🫁 transplant with no signs of rejections.
Incredible science showed at #ISHLT2025 @ishlt.bsky.social
Incredible science showed at #ISHLT2025 @ishlt.bsky.social
April 30, 2025 at 4:44 PM
It’s AB0ut time we talk with Dr Aversa about AB0! Super interesting case of an 0 patient receiving nonA1 🫁 transplant with no signs of rejections.
Incredible science showed at #ISHLT2025 @ishlt.bsky.social
Incredible science showed at #ISHLT2025 @ishlt.bsky.social
Followed by Dr Guillaime Coutance guiding us through PRAs. Which antibodies should we look for and how to measure???
Dr Lyster showed us what to do with highly sensitised patients pre and post transplant.
#ISHLT2025
Dr Lyster showed us what to do with highly sensitised patients pre and post transplant.
#ISHLT2025
April 30, 2025 at 4:41 PM
Followed by Dr Guillaime Coutance guiding us through PRAs. Which antibodies should we look for and how to measure???
Dr Lyster showed us what to do with highly sensitised patients pre and post transplant.
#ISHLT2025
Dr Lyster showed us what to do with highly sensitised patients pre and post transplant.
#ISHLT2025
And last day at #ISHLT2025 we go through the consensus statement with Dr Annette Jackson. Amazing talk on the use of antibodies in transplant.
@ishlt.bsky.social
@ishlt.bsky.social
April 30, 2025 at 4:38 PM
And last day at #ISHLT2025 we go through the consensus statement with Dr Annette Jackson. Amazing talk on the use of antibodies in transplant.
@ishlt.bsky.social
@ishlt.bsky.social
Did you get the reference?
April 29, 2025 at 2:33 PM
Did you get the reference?
🎯 Dr. Tomas Pulido presented Out of the woods: High-altitude PAH. This subset of PAH is seen frequently in certain areas of south America and tend to improve with meds and moving to low altitude areas.
April 29, 2025 at 2:32 PM
🎯 Dr. Tomas Pulido presented Out of the woods: High-altitude PAH. This subset of PAH is seen frequently in certain areas of south America and tend to improve with meds and moving to low altitude areas.
🎯 Dr Valentina Stosor presented Shake it Off: HIV associated PAH. HIV infection induces changes in the PA other than from direct infection. Drugs interactions are frequent between PA vasodilators and ART.
April 29, 2025 at 2:30 PM
🎯 Dr Valentina Stosor presented Shake it Off: HIV associated PAH. HIV infection induces changes in the PA other than from direct infection. Drugs interactions are frequent between PA vasodilators and ART.
🎯 Dr Camila Loureiro presented I forgot that you existed: Schistosomiasis-Associated pulmonary arterial hypertension. Schistosoma is extremely frequent in certain areas of Africa, Asia and Brazil. We dipped dig on the treatments and diagnosis of such a rare subset of disease.
April 29, 2025 at 2:29 PM
🎯 Dr Camila Loureiro presented I forgot that you existed: Schistosomiasis-Associated pulmonary arterial hypertension. Schistosoma is extremely frequent in certain areas of Africa, Asia and Brazil. We dipped dig on the treatments and diagnosis of such a rare subset of disease.
🎯 Dr Hooman Poor presented Bad Blood: Pulmonary Hypertension, Hematologic disorder and Bone Marrow Transplant. Sickle cell, dasatinib associated PAH and mieloproliferative disease
April 29, 2025 at 2:27 PM
🎯 Dr Hooman Poor presented Bad Blood: Pulmonary Hypertension, Hematologic disorder and Bone Marrow Transplant. Sickle cell, dasatinib associated PAH and mieloproliferative disease
🎯 Dr Arun Jose presented: When the liver is the source of evil: porto-pulmonary HTN and liver transplantation.
PoP-PH is different from Hepato-pulmonary syndrome, which tends to regress after liver transplant. Liver transplant can improve PoP-PH though PH can persist.
PoP-PH is different from Hepato-pulmonary syndrome, which tends to regress after liver transplant. Liver transplant can improve PoP-PH though PH can persist.
April 29, 2025 at 2:26 PM
🎯 Dr Arun Jose presented: When the liver is the source of evil: porto-pulmonary HTN and liver transplantation.
PoP-PH is different from Hepato-pulmonary syndrome, which tends to regress after liver transplant. Liver transplant can improve PoP-PH though PH can persist.
PoP-PH is different from Hepato-pulmonary syndrome, which tends to regress after liver transplant. Liver transplant can improve PoP-PH though PH can persist.
🎯 Dr Arun Jose presented: When the liver is the source of evil: porto-pulmonary HTN and liver transplantation.
PoP-PH is different from Hepato-pulmonary syndrome, which tends to regress after liver transplant. Liver transplant can improve PoP-PH though PH can persist.
PoP-PH is different from Hepato-pulmonary syndrome, which tends to regress after liver transplant. Liver transplant can improve PoP-PH though PH can persist.
April 29, 2025 at 2:25 PM
🎯 Dr Arun Jose presented: When the liver is the source of evil: porto-pulmonary HTN and liver transplantation.
PoP-PH is different from Hepato-pulmonary syndrome, which tends to regress after liver transplant. Liver transplant can improve PoP-PH though PH can persist.
PoP-PH is different from Hepato-pulmonary syndrome, which tends to regress after liver transplant. Liver transplant can improve PoP-PH though PH can persist.
What is the role of MCS in PAH and cardiogenic shock?
1) patient selection
2) choose the RIGHT access
3) have an exit strategy in view
4) start PH therapies
5) consider transplant
These are few of the points we discussed today with Dr Sommer @ishlt.bsky.social
#ISHLT #PAH #PH
1) patient selection
2) choose the RIGHT access
3) have an exit strategy in view
4) start PH therapies
5) consider transplant
These are few of the points we discussed today with Dr Sommer @ishlt.bsky.social
#ISHLT #PAH #PH
April 28, 2025 at 7:02 PM
What is the role of MCS in PAH and cardiogenic shock?
1) patient selection
2) choose the RIGHT access
3) have an exit strategy in view
4) start PH therapies
5) consider transplant
These are few of the points we discussed today with Dr Sommer @ishlt.bsky.social
#ISHLT #PAH #PH
1) patient selection
2) choose the RIGHT access
3) have an exit strategy in view
4) start PH therapies
5) consider transplant
These are few of the points we discussed today with Dr Sommer @ishlt.bsky.social
#ISHLT #PAH #PH
What can you do when a patient with PH land in the ICU with Shock?
Dr Mads Andersen walks us through
Preload treatment
Inotropes and its use
Afterload for PH
Important talk @ishlt.bsky.social #ISHLT2025 #PH
Dr Mads Andersen walks us through
Preload treatment
Inotropes and its use
Afterload for PH
Important talk @ishlt.bsky.social #ISHLT2025 #PH
April 28, 2025 at 7:01 PM
What can you do when a patient with PH land in the ICU with Shock?
Dr Mads Andersen walks us through
Preload treatment
Inotropes and its use
Afterload for PH
Important talk @ishlt.bsky.social #ISHLT2025 #PH
Dr Mads Andersen walks us through
Preload treatment
Inotropes and its use
Afterload for PH
Important talk @ishlt.bsky.social #ISHLT2025 #PH
And from the Right Ventricle- Right atria interaction we move to the complex relationship between heart - kidneys and lungs in PH with an amazing talk from Dr. Rosenkranz.
#ISHLT2025 #PAH #PH
@ishlt.bsky.social
#ISHLT2025 #PAH #PH
@ishlt.bsky.social
April 28, 2025 at 7:00 PM
And from the Right Ventricle- Right atria interaction we move to the complex relationship between heart - kidneys and lungs in PH with an amazing talk from Dr. Rosenkranz.
#ISHLT2025 #PAH #PH
@ishlt.bsky.social
#ISHLT2025 #PAH #PH
@ishlt.bsky.social
Today we dig deep in the pathophys of PH #ISHLT2025 with Dr Frances De Man on pressure loop of the RA.
Super interesting discussion on what happens to myocites in the right atrium.
@ishlt.bsky.social #PAH #PH
Super interesting discussion on what happens to myocites in the right atrium.
@ishlt.bsky.social #PAH #PH
April 28, 2025 at 6:59 PM
Today we dig deep in the pathophys of PH #ISHLT2025 with Dr Frances De Man on pressure loop of the RA.
Super interesting discussion on what happens to myocites in the right atrium.
@ishlt.bsky.social #PAH #PH
Super interesting discussion on what happens to myocites in the right atrium.
@ishlt.bsky.social #PAH #PH
We finished with Dr David Jenkins and CTEPH talks.
When confirmed CTEPH we should ask:
🟢is patient operable? If YES PTE
NO?
🟢Can we do BPA?
NO?
🟢Riociguat
New direction? Can we combine such treatments for high risk patients?
When confirmed CTEPH we should ask:
🟢is patient operable? If YES PTE
NO?
🟢Can we do BPA?
NO?
🟢Riociguat
New direction? Can we combine such treatments for high risk patients?
April 27, 2025 at 8:39 PM
We finished with Dr David Jenkins and CTEPH talks.
When confirmed CTEPH we should ask:
🟢is patient operable? If YES PTE
NO?
🟢Can we do BPA?
NO?
🟢Riociguat
New direction? Can we combine such treatments for high risk patients?
When confirmed CTEPH we should ask:
🟢is patient operable? If YES PTE
NO?
🟢Can we do BPA?
NO?
🟢Riociguat
New direction? Can we combine such treatments for high risk patients?
We also talked about group 3 PH with Dr Shlobin Oksana. The different pathophysiology of it and possible treatment options.
Differentiate between:
🟢COPD-PH
🟢CPFE-PH
🟢ILD-PH
More studies are needed with better characterisation of PFTs for therapeutic target.
Differentiate between:
🟢COPD-PH
🟢CPFE-PH
🟢ILD-PH
More studies are needed with better characterisation of PFTs for therapeutic target.
April 27, 2025 at 8:39 PM
We also talked about group 3 PH with Dr Shlobin Oksana. The different pathophysiology of it and possible treatment options.
Differentiate between:
🟢COPD-PH
🟢CPFE-PH
🟢ILD-PH
More studies are needed with better characterisation of PFTs for therapeutic target.
Differentiate between:
🟢COPD-PH
🟢CPFE-PH
🟢ILD-PH
More studies are needed with better characterisation of PFTs for therapeutic target.
We also talked with Dr Jessica Huston about PH in LHD (group 2).
Zone of uncertainties (PCWP 12 - 18) use other modalities to help with the diagnosis like echo etc.
Think about PH-LHD in stages:
A at risk
B structural heart disease
C symptomatic patient
D predominant RVF
Zone of uncertainties (PCWP 12 - 18) use other modalities to help with the diagnosis like echo etc.
Think about PH-LHD in stages:
A at risk
B structural heart disease
C symptomatic patient
D predominant RVF
April 27, 2025 at 8:38 PM
We also talked with Dr Jessica Huston about PH in LHD (group 2).
Zone of uncertainties (PCWP 12 - 18) use other modalities to help with the diagnosis like echo etc.
Think about PH-LHD in stages:
A at risk
B structural heart disease
C symptomatic patient
D predominant RVF
Zone of uncertainties (PCWP 12 - 18) use other modalities to help with the diagnosis like echo etc.
Think about PH-LHD in stages:
A at risk
B structural heart disease
C symptomatic patient
D predominant RVF
Following @ChristianGerges summarised the treatment of PAH and the new algorithm.
🟢 not high risk start with dual oral therapy
🔴High risk: triple therapy up front with IV prostanoids
Frequent re-assessment is key with uptitration of therapy to achieve a low risk profile.
🟢 not high risk start with dual oral therapy
🔴High risk: triple therapy up front with IV prostanoids
Frequent re-assessment is key with uptitration of therapy to achieve a low risk profile.
April 27, 2025 at 8:37 PM
Following @ChristianGerges summarised the treatment of PAH and the new algorithm.
🟢 not high risk start with dual oral therapy
🔴High risk: triple therapy up front with IV prostanoids
Frequent re-assessment is key with uptitration of therapy to achieve a low risk profile.
🟢 not high risk start with dual oral therapy
🔴High risk: triple therapy up front with IV prostanoids
Frequent re-assessment is key with uptitration of therapy to achieve a low risk profile.